According to the most current research data, the HIF-1 inhibitor echinomycin enhanced the anti-CTLA-4 treatment’s cancer immunotherapy effectiveness, with efficacy comparable to anti-CTLA-4 + anti-PD-1 antibodies [195]. Here, HIF1A is linked to cancer.